Influence of Antithrombin III on Coagulation and Inflammation in Porcine Septic Shock
- 1 June 1999
- journal article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 19 (6), 1566-1572
- https://doi.org/10.1161/01.atv.19.6.1566
Abstract
—The physiological inhibitor of thrombin, antithrombin III (ATIII, Kybernin P) was investigated for its antiinflammatory and anticoagulant effects in a pig model of septic shock. Pigs were infused with a dose of 0.25 μg · kg−1 · h−1 of lipopolysaccharide (LPS) over a period of 3 hours. Animals developed systemic inflammation, disseminated intravascular coagulation (DIC), organ failure and cardiovascular abnormalities, namely pulmonary hypertension and systemic hypotension. Twenty septic pigs were allocated to 2 study groups, treated either with ATIII (n=10) or placebo (n=10). ATIII was administered as a 250-U/kg IV bolus infusion for 30 minutes (−60 to −30 minutes) followed by a single IV bolus of 125 U/kg (t=0) and a second 30-minute infusion of 250 U/kg (120 to 150 minutes). ATIII significantly prevented the development of a DIC; the increase in fibrin monomers (placebo, 11.4±9.1 reciprocal titers, at 6 hours) was completely overcome by ATIII (P2) levels, which were 809±287 pg/mL in the placebo and 420±174 pg/mL in the verum group after 6 hours (P−1 · h−1). A significant reduction in mortality was observed in the ATIII group (0 of 7) compared with the placebo group (4 of 6) (P2 test) a significant reduction of pulmonary hypertension (placebo, 42.0±11.1 mm Hg; ATIII, 23.6±7.5 mm Hg, P<0.05), but no effect on systemic hypotension, was noted in the ATIII group. It was thus concluded that modulation of the procoagulatory state by substitution of ATIII results in a late beneficial antiinflammatory effect in this model of septic shock.Keywords
This publication has 31 references indexed in Scilit:
- Antithrombin III in Animal Models of Sepsis and Organ FailureSeminars in Thrombosis and Hemostasis, 1998
- Disseminated Intravascular Coagulation: Objective Clinical and Laboratory Diagnosis, Treatment, and Assessment of Therapeutic ResponseSeminars in Thrombosis and Hemostasis, 1996
- Antithrombin III in Shock and Disseminated Intravascular CoagulationClinical and Applied Thrombosis/hemostasis, 1995
- Regulation of Thrombin Activity by Antithrombin and HeparinSeminars in Thrombosis and Hemostasis, 1994
- Antithrombin: The Principal Inhibitor of ThrombinSeminars in Thrombosis and Hemostasis, 1994
- CD14: Cell surface receptor and differentiation markerImmunology Today, 1993
- Antithrombin III: physiology, deficiency, and replacement therapyTransfusion, 1992
- Human Antithrombin Concentrates and Experimental Disseminated Intravascular CoagulationSeminars in Thrombosis and Hemostasis, 1985
- Interaction of antithrombin III with bovine aortic segments. Role of heparin in binding and enhanced anticoagulant activity.Journal of Clinical Investigation, 1985
- Antithrombin III: Protection against Death after Injection of ThromboplastinScience, 1969